Premium
Herpes vector–mediated expression of proenkephalin reduces bone cancer pain
Author(s) -
Goss James R.,
Harley Cara F.,
Mata Marina,
O'Malley Mark E.,
Goins William F.,
Hu Xiaoping,
Glorioso Joseph C.,
Fink David J.
Publication year - 2002
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.10343
Subject(s) - vector (molecular biology) , herpes simplex virus , medullary cavity , medicine , nociception , cancer pain , bone cancer , viral vector , cancer research , virology , virus , cancer , biology , pathology , recombinant dna , gene , receptor , biochemistry
We examined whether a herpes simplex virus vector that expresses human proenkephalin could be used to attenuate nociception in a model of bone cancer pain in mice. Osteolytic sarcoma cells were implanted into the medullary space of the right femur, followed by a subcutaneous inoculation of a replication‐defective herpes simplex virus vector expressing human proenkephalin (vector SHPE) or a lacZ‐expressing control vector (vector SHZ). SHPE‐inoculated mice demonstrated a significant, naltrexone‐reversible decrease in pain‐related behavior assessed during open‐field motor activity. These results suggest that gene transfer with an enkephalin‐expressing vector may be used to treat pain resulting from cancer in bone.